Kinzey Capital Management: Electra Sets Nasdaq IPO Terms

Electra Therapeutics is pricing 21.7 million shares at $14-$16 each on Nasdaq under ticker ETRA, targeting up to $347 million to advance ipsoprubart through its SURPASS registration trial for secondary haemophagocytic lymphohistiocytosis. The offering values the clinical-stage antibody developer near $1 billion, with frontline data showing 100% overall survival at eight weeks versus historical 20-30% mortality rates.